NICE draft guidance on tests to target Erbitux better
This article was originally published in Scrip
Executive Summary
NICE, the health technology appraisal institute for England and Wales, has published draft guidance recommending a number of tests to help doctors target treatment with Merck KGaA/ Bristol-Myers Squibb 's Erbitux (cetuximab) more effectively in people with advanced (metastatic) colorectal cancer.